Comments
Drug major Lupin has launched a generic version of Japan-headquartered Eisai Inc’s Aciphex delayed-release tablets, used to treat gastroesophageal reflux disease, in the US market.
The company’s US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market, after having received approval from the US Food and Drug Administration to market it, according to a statement by Lupin.
Lupin’s product is generic equivalent of Eisai Inc’s Aciphex delayed-release tablets, 20 mg, and it is indicated for the treatment of gastroesophageal reflux disease (GERD), it added.
According to IMS MAT June 2013 sales data, Aciphex delayed-release tablets, 20 mg, had annual US sales of around $864.3 million.
Shares of Lupin were trading at Rs 886.30 a piece on the BSE in the late afternoon trade, up 0.3 per cent from their previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.